摘要
我国新修订的《专利法》所确立的药品专利期补偿制度,旨在通过延长药品专利权期限来激发药企的创新研发,进而推动医药产业创新升级,但其作为一项“外来”制度,在补偿保护对象、适用范围、审批程序以及监督措施等诸多环节皆存在适用困境,需要在本土化设计上予以完善。
China's newly revised Patent Law establishes the drug patent term compensation system,which aims to stimulate the in⁃novation and development of pharmaceutical companies by extending the patent term of drugs,and then promote the innovation and up⁃grading of the pharmaceutical industry.However,as an"external"system,there are application difficulties in many aspects such as compensation protection object,application scope,approval procedure and supervision measures.Therefore it is necessary to improve the localization design.
作者
王业凡
WANG Yefan(Zhongnan University of Economics and Law,Wuhan,Hubei 430073,China)
出处
《医学与法学》
2024年第6期87-94,共8页
Medicine and Jurisprudence
基金
四川医事卫生法治研究中心-中国卫生法学会2023年联合资助项目“应对重大突发公共卫生事件的药品专利制度体系研究”(项目编号:YF23-Q01)的阶段性成果。
关键词
药品专利
专利期补偿
利益平衡
可竞争市场
pharmaceutical patents
patent term compensation
interests balance
competitive market
